Progynova 1mg Tablet

Progynova 1mg Tablet contains estradiol valerate 1mg, a lower-dose form of oestrogen used in hormone replacement therapy (HRT) to relieve menopausal symptoms such as hot flashes, night sweats, and vaginal dryness, and it is commonly used either as a starting dose for women new to HRT or as a step-down dose for women whose symptoms are already well controlled on a higher strength. In women who still have their womb, Progynova 1mg Tablet is typically prescribed alongside a progestogen to protect the womb lining from unopposed oestrogen stimulation.

As Progynova 1mg Tablet is a prescription-only hormone medicine, it is supplied through DoctorOnCall only after an online consultation with a doctor, who will review your medical history, menopausal symptoms, and personal risk factors such as history of blood clots, breast cancer, or liver disease before confirming whether this lower starting dose is appropriate for you.

Progynova 1mg Tablet works by replenishing the body’s oestrogen (specifically estradiol) at a lower dose than the 2mg strength, helping to reduce vasomotor symptoms such as hot flashes and night sweats and support vaginal tissue health, while allowing your doctor to find the lowest effective dose that controls your symptoms with the least hormonal exposure.

Take Progynova 1mg Tablet exactly as prescribed by your doctor, usually one tablet daily at the same time each day, swallowed whole with water; your doctor will advise whether you are on a continuous or cyclic regimen, and if a progestogen is also prescribed, both medicines should be taken according to the specific schedule given.

The typical dose is one 1mg tablet daily, often used as a starting dose for HRT or as a maintenance dose once symptoms are controlled on a higher strength, with your doctor adjusting up or down as needed to find the lowest effective dose for the shortest duration required.

Progynova 1mg Tablet is generally stable for up to 3 to 5 years from the date of manufacture when unopened, so always check the expiry date printed on the blister strip or carton before use.

Store Progynova 1mg Tablet below 30°C in a dry place away from direct sunlight and moisture, and keep it out of the sight and reach of children.

• Known, past, or suspected breast cancer or other oestrogen-dependent cancer
• Undiagnosed abnormal vaginal bleeding
• Current or past history of venous thromboembolism (blood clots) or a known clotting disorder
• Active or recent arterial disease such as heart attack or stroke
• Severe liver disease or liver tumours
• Known or suspected pregnancy

• Enzyme-inducing medicines such as rifampicin, certain anticonvulsants (for example carbamazepine or phenytoin), and St John’s Wort may reduce the effectiveness of Progynova 1mg Tablet
• Concurrent use with tamoxifen may reduce tamoxifen’s effectiveness and should be discussed with your doctor
• Anticoagulants such as warfarin may require closer monitoring when started or stopped alongside HRT
• Grapefruit juice may in some cases increase estradiol blood levels; discuss significant dietary changes with your doctor

• Progynova 1mg Tablet is often used as a starting or step-down dose — do not change your dose without your doctor’s guidance
• Attend regular follow-up appointments, including breast checks and mammograms as recommended for your age group
• Report any new, unusual, or heavy vaginal bleeding to your doctor promptly
• Give the tablet a few weeks to take effect before assuming your current dose is not working, and discuss any concerns at your next review
• Inform your doctor of any new medical conditions or medicines started while on Progynova 1mg Tablet

Progynova 1mg Tablet is often the preferred starting strength for women beginning hormone replacement therapy, or a step-down option once menopausal symptoms have stabilised on a higher dose, reflecting the general principle of using the lowest effective HRT dose. Because HRT carries risks that vary with age, time since menopause, and personal health history, DoctorOnCall’s doctors review each customer individually through an online consultation and recommend appropriate monitoring, including periodic reassessment of ongoing need.